VIRBAC Announces Third Quarter 2025 Sales Sustained revenue growth at the end of September of +7.8% at constant exchange rates and scopeUpgrade of the full-year revenue guidance Revenue growth now expected to be between 5.5% and 7.5% at constant rates and scopeAdjusted recurring operating income¹ expected around 16% Press release on October 16, 2025, after market close at 5:45 p.m. CEST KEY FIGURES Revenue in first half of 2025 €1102.4M Growth at constant exchange rates and scope2 +7.8 including companion animals +11.3% farm animals +6.1% Growth at constant ...
VIRBAC annonce son chiffre d'affaires pour le troisième trimestre 2025 Croissance soutenue du chiffre d’affaires à fin septembre de +7,8% à taux de change et périmètre constantsRelèvement des objectifs financiers annuels de chiffre d’affaires Croissance du chiffre d'affaires attendue maintenant entre 5,5% et 7,5% à taux et périmètre constants Résultat opérationnel courant ajusté1 attendu autour de 16% Communiqué diffusé le 16 octobre 2025 après bourse à 17h45 CEST CHIFFRES CLÉSChiffre d’affaires à fin septembre 20251102,4 M€Croissance à taux de change et périmètre constants2+7,8% dont an...
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies 50 mg dose of once-daily obefazimod achieved clinically meaningful improvements, across all endpoints, regardless of prior inadequate response to advanced therapies (AT-IR) 50mg dose demonstrated clinically meaningful improvements in clinical remission in particip...
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p
GTT: Monthly disclosure of the total number of voting rights and shares composing the share capital Monthly disclosure of the total number of voting rights and shares composing the share capital Articles L. 233-8-II of the French Commercial Code and 223-16 of the General Regulation of the Autorité des Marchés Financiers Saint-Rémy-lès-Chevreuse, October 3, 2025 DateTotal number of sharesTheoretical total number of voting rights1Net total number of voting rights2September 30, 202537,117,77237,117,77237,064,515 Investor Relations Contact / 87 1 Calculat...
GTT : Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Articles L. 233-8-II du Code de commerce et 223-16 du Règlement général de l’Autorité des marchés financiers Saint-Rémy-lès-Chevreuse, le 3 octobre 2025 DateNombre total d’actions composant le capitalNombre total de droits de vote théoriques1Nombre total de droits de vote nets230 septembre 202537 117 77237 117 77237 064 515 Contact Relations Investisseurs : / 87 ...
Virbac : Declaration of the number of shares and voting rights 09/2025 DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsSeptember, 30 20258 390 660Gross total of voting rights : 12 705 441Net total* of voting rights : 12 692...
Virbac : Déclaration d'actions et de droits de vote 09/2025 DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place cotation : Euronext ParisCompartiment ACode ISIN : FR0000031577 DATENombre total d’actions composant le capital socialNombre total de droits de vote30 Septembre 20258 390 660Total brut de droits de vote : 12 705 441Total net* de droits de vote : 12 692 605 Total net* = nombre total de droits de vote attachés a...
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting Abivax Announces Acceptance of AdditionalLate-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract titled EFFICACY AND SAFETY OF OBEFAZIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM TWO, PHASE 3, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 8-WEEK INDUCTION TRIALS (ABTECT-1 & 2) ...
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting Late Breaking Abstract titled EFFICACY OF OBEFAZIMOD IN ABTECT PHASE 3 INDUCTION TRIALS: RESULTS OF 8-WEEK THERAPY IN SUBSETS OF PATIENTS WITH AND WITHOUT PRIOR INADEQUATE RESPONSE TO ADVANCED THERAPIES to be presented Monday, October 6 at 10am CET Abivax manage...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.